Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stacy Loeb

Showing results (81-90 of 498) with videos related to

Pageof 50
Sort By:
Reviews in Urology|April 30, 2010
What is the true mortality benefit of prostate-specific antigen screening?Stacy Loeb, Alan W Partin
Primary Care|July 21, 2009
Risk factors, prevention and early detection of prostate cancerStacy Loeb, Edward M Schaeffer
Oncology (Williston Park, N.Y.)|October 21, 2009
Optimal therapy in localized prostate cancer: an unfolding storyStacy Loeb, Edward M Schaeffer
Current Oncology Reports|April 14, 2007
The role of high-intensity focused ultrasound in prostate cancerJohn H Lynch, Stacy Loeb
Urologic Oncology|April 5, 2011
Prostate-specific antigen (PSA) should drive doing prostate biopsiesStacy Loeb, William J Catalona
Urologic Oncology|May 9, 2006
Making prostate-specific antigen testing more effectiveWilliam J Catalona, Stacy Loeb
Urologic Oncology|November 3, 2009
Limitations and use of PSA derivatives in the screening and risk stratification of prostate cancerStacy Loeb, H Ballentine Carter
Reviews in Urology|January 11, 2012
Review of the literature: PCA3 for prostate cancer risk assessment and prognosticationStacy Loeb, Alan W Partin
Oncology (Williston Park, N.Y.)|January 17, 2017
Active Surveillance of Prostate CancerPeter L Choyke, Stacy Loeb
European Urology|January 28, 2025
Shining a Light in the Darkness: Exploring Treatment Burden in Genitourinary OncologyAlicia K Morgans, Stacy Loeb
Pageof 50

Showing results (81-90 of 498) with videos related to

Sort By:
Pageof 50
Reviews in Urology|April 30, 2010
What is the true mortality benefit of prostate-specific antigen screening?Stacy Loeb, Alan W Partin
Primary Care|July 21, 2009
Risk factors, prevention and early detection of prostate cancerStacy Loeb, Edward M Schaeffer
Oncology (Williston Park, N.Y.)|October 21, 2009
Optimal therapy in localized prostate cancer: an unfolding storyStacy Loeb, Edward M Schaeffer
Current Oncology Reports|April 14, 2007
The role of high-intensity focused ultrasound in prostate cancerJohn H Lynch, Stacy Loeb
Urologic Oncology|April 5, 2011
Prostate-specific antigen (PSA) should drive doing prostate biopsiesStacy Loeb, William J Catalona
Urologic Oncology|May 9, 2006
Making prostate-specific antigen testing more effectiveWilliam J Catalona, Stacy Loeb
Urologic Oncology|November 3, 2009
Limitations and use of PSA derivatives in the screening and risk stratification of prostate cancerStacy Loeb, H Ballentine Carter
Reviews in Urology|January 11, 2012
Review of the literature: PCA3 for prostate cancer risk assessment and prognosticationStacy Loeb, Alan W Partin
Oncology (Williston Park, N.Y.)|January 17, 2017
Active Surveillance of Prostate CancerPeter L Choyke, Stacy Loeb
European Urology|January 28, 2025
Shining a Light in the Darkness: Exploring Treatment Burden in Genitourinary OncologyAlicia K Morgans, Stacy Loeb
Pageof 50